A Quick Look at Using Meningococcal Conjugate Vaccines (MCV4)

Age Indications for MCV4 Vaccines
Menactra® & Menveo® are approved for ages 2 through 55 years

Indications for Use and Schedule
- Routinely administer:
  - One dose at ages 11-12 years & a booster dose at age 16 years
- Adolescent catch-up schedule:
  - If 1st dose at ages 13 through 15 years, give a booster dose at ages 16 through 18 years
  - If 1st dose at age 16 years or older, a booster dose is not recommended
  - Healthy persons older than age 21 years (who are not at increased risk for disease) do not need any routine doses
  - A 3-5 year interval is preferred between doses
- Other persons at high risk for disease*: see below
- Minimum interval
  - 8 weeks between 2 doses

Vaccine Administration
- Intramuscular (IM) injection in the deltoid of the arm
- 1-1.5 inch, 22-25 gauge needle
- Use professional judgment in selecting needle length
- Can be given simultaneously with other vaccines

Storage and Handling
- Store in the refrigerator between 35º-46º F (2º-8º C)
- Do NOT freeze
- Keep in the original box
- Shake well before using
- Menactra is ready to use
- MENVEO must be reconstituted using MenCYW-135 conjugate diluent supplied with the vaccine. Use single-dose vials immediately after reconstitution

* PERSONS WITH CERTAIN MEDICAL OR OTHER CONDITIONS
- For persons 2-55 years with persistent terminal complement deficiency or asplenia (functional or anatomic):
  - Give a 2-dose primary series (0, 2 mo) and a booster dose every 5 years
- For adolescents ages 11 through 18 years with HIV infection**:
  - Give a 2-dose primary series (0, 2 mo) and then follow the adolescent schedule (above)
- For children ages 2-10 years & adults ages 19-55 years with HIV infection** and another risk factor, give a 2-dose primary series
  - Need for a booster dose is determined by the risk factor (e.g., travel, being of adolescent age)
- For persons who are at increased risk due to prolonged exposure (e.g., travel to or living in endemic areas, current outbreak, microbiologists exposed to N. meningitides) or when required (e.g., military recruits, travel to Mecca during annual Hajj):
  - Give a 1-dose primary series
  - If the person remains at increased risk, a booster dose is recommended
    - For children vaccinated at ages 2 through 6 years: after 3 years
    - For persons vaccinated at ages 7 years & older: after 5 years
- Ensure college/university students, ages 21 years or younger, have received at least one dose of MCV4 in the last 5 years
** HIV infection, without another risk factor present, is not a medical indication for meningococcal vaccination

CONTRAINDICATIONS
- An anaphylactic reaction to a prior dose of MCV4 vaccine
- An anaphylactic reaction to a component of MCV4 vaccine
- A history of Guillain-Barré Syndrome (use MPSV4-meningococcal polysaccharide vaccine [Menomune®] if vaccination is needed)

PRECAUTIONS
- Moderate to severe acute illness

FURTHER POINTS
- Persons with asplenia, complement component deficiency or HIV who previously received only a 1-dose primary series, should get a 2nd dose as soon as feasible
- Persons ages 2 through 55 years who inadvertently receive MPSV4 should be revaccinated with MCV4 (minimum interval 8 wks)
- Both MCV4 vaccines contain serotypes A, C, Y, and W-135. Serotype B is not in either vaccine.
- Meningococcal Vaccine Information Statement (VIS), including information about the Michigan Care Improvement Registry (MCIR), can be found at www.michigan.gov/immunize or your local health department
- Document Menactra as “MCV4 (Menactra)” & MENVEO as “MCV4 (MENVEO)” in MCIR
- Document both as “MCV4” on the vaccine administration record (VAR) & immunization record card
- Document the lot number on the outside box of MENVEO in MCIR and on the VAR

Publicly purchased MCV4 can be administered to eligible children 2 through 18 years of age with an indication for vaccination through the Vaccines for Children (VFC) Program in private providers’ offices. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information


Updates to this Quick Look handout will be posted at www.michigan.gov/immunize under Provider Information.

March 16, 2011